ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock Has Consensus Price Target of $4.60 According to Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $4.60.

Separately, Weiss Ratings upgraded ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Beacon Pointe Advisors LLC acquired a new stake in ALX Oncology in the second quarter valued at about $26,000. Callan Family Office LLC acquired a new position in ALX Oncology during the 2nd quarter worth approximately $46,000. The Manufacturers Life Insurance Company acquired a new position in ALX Oncology during the 2nd quarter worth approximately $64,000. AXQ Capital LP acquired a new position in ALX Oncology during the 2nd quarter worth approximately $84,000. Finally, Squarepoint Ops LLC purchased a new position in shares of ALX Oncology during the 2nd quarter worth approximately $97,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $1.22 on Thursday. ALX Oncology has a one year low of $0.86 and a one year high of $2.66. The stock has a market capitalization of $168.70 million, a price-to-earnings ratio of -1.08 and a beta of 0.47. The company has a 50-day simple moving average of $1.51 and a 200-day simple moving average of $1.82. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, analysts predict that ALX Oncology will post -0.59 EPS for the current year.

About ALX Oncology

ALX Oncology Holdings Inc (NASDAQ: ALXO) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. The company’s research centers on the CD47-SIRP? pathway, an immune checkpoint that cancer cells can use to evade detection and destruction by the immune system.

ALX Oncology’s lead product candidate is evorpacept, also known as ALX148, an investigational protein designed to block CD47 while supporting the activity of therapeutic antibodies and other anti-cancer treatments.